Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

By afschroeder • September 25, 2025

Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani S, Jang CW, Clarke JM, Tchekmedyian N, Goldman JW, Socinski M, Bhat G, Leu S, Bunn V, Su Z, Vincent S, Lawson JW, Cross JB, Heymach JV. Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity. Nat Commun. 2025 Sep 24;16(1):8358. doi: 10.1038/s41467-025-61817-8. PMID: 40993146.

Tags: Hematology/Oncology, Publications

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison[...]

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]

Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies

Ramesh K, Hui G, Shodiya M, Palaskas NJ. Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies. Cureus. 2026 Jul 29;18(7):e113621. doi: 10.7759/cureus.113621.[...]